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 Highlights 
• 
We developed a NGS array for hypophosphatasia (HPP) and differential diagnosis 
genes. 
• 
Patients referred for HPP diagnosis may have mutations in COL1A1 or COL1A2 
genes. 
• 
Testing together ALPL, COL1A1 and COL1A2 genes was proven efficient and useful. 
Abstract 
Hypophosphatasia (HPP) is a rare inherited skeletal dysplasia due to loss of function 
mutations in the ALPL gene. The disease is subject to an extremely high clinical heterogeneity 
ranging from a perinatal lethal form to odontohypophosphatasia affecting only teeth. Up to 
now genetic diagnosis of HPP is performed by sequencing the ALPL gene by Sanger 
methodology. Osteogenesis imperfecta (OI) and campomelic dysplasia (CD) are the main 
differential diagnoses of severe HPP, so that in case of negative result for ALPL mutations, OI 
and CD genes had often to be analyzed, lengthening the time before diagnosis. We report here 
our 18-month experience in testing 46 patients for HPP and differential diagnosis by targeted 
NGS and show that this strategy is efficient and useful. We used an array including ALPL 
gene, genes of differential diagnosis COL1A1 and COL1A2 that represent 90% of OI cases, 
SOX9, responsible for CD, and 8 potentially modifier genes of HPP. Seventeen patients were 
found to carry a mutation in one of these genes. Among them, only 10 out of 15 cases referred 
for HPP carried a mutation in ALPL and 5 carried a mutation in COL1A1 or COL1A2. 
Interestingly, three of these patients were adults with fractures and/or low BMD. Our results 
indicate that HPP and OI may be easily misdiagnosed in the prenatal stage but also in adults 
with mild symptoms for these diseases. 
Keywords 
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1. Introduction 
Hypophosphatasia (HPP) is a rare inherited skeletal dysplasia due to loss-of-function 
mutations in the ALPL gene encoding the Tissue Nonspecific Alkaline Phosphatase 
(TNSALP) [1]. Although the clinical spectrum is a continuum, HPP has been divided into 6 
clinical subtypes that may however significantly overlap [2]. The perinatal form is the most 
severe one and is almost always lethal. The patients die a few days after birth due to 
respiratory distress and seizures. They present with hypoplasic lungs, extensive 
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hypomineralization, deformities of bone, severe hypercalcemia and hyperphosphatemia likely 
due to the lack of mineral deposition on the bones. In the prenatal benign form, despite 
prenatal symptoms, spontaneous improvement of the skeletal defects might occur completely 
or partially, resulting in nonlethal HPP [3], [4] and [5]. Clinical signs of the infantile form 
appear during the first 6 months of life and include rickets, premature craniosynostosis, 
respiratory issues, irritability, seizures and nephrocalcinosis due to hypercalciuria. This form 
is lethal in approximately 50% of the cases. Childhood HPP mostly occurs after the first year 
of life and is characterized by rickets causing a short stature, delayed walking and a waddling 
gait due to bone deformities and pain of the lower extremities. Premature loss of teeth often 
leads to the diagnosis. Adult HPP presents with osteomalacia, chondrocalcinosis, 
osteoarthropathy and stress fractures during middle age in patients who had a history of mild 
rickets in childhood. Many patients present premature loss of permanent teeth. 
Odontohypophosphatasia (odontoHPP) is characterized by dental manifestations of HPP not 
associated with abnormalities of the skeletal system. 
This high clinical heterogeneity is mainly due to the great number of ALPL missense 
mutations [6], more rarely to other factors as suggested by clinical heterogeneity observed 
between patients with the same ALPL genotype [7], [8], [9] and [10] and even between 
affected siblings [11]. Interestingly, a recent report showed that screening for low serum 
alkaline phosphatase (ALP) in patients with low bone mineral density (BMD) evidenced 
heterozygous ALPL sequence variations in 33.8% of these patients vs 1.4% in controls with 
normal BMD [12]. Thus the role of ALPL mutations in various conditions such as 
osteoporosis is emerging. 
There are various differential diagnoses of HPP [13]. They depend on the age at which the 
diagnosis is considered. In utero, osteogenesis imperfecta (OI) type II and campomelic 
dysplasia (CD) are the most common differential diagnoses of HPP. Rare conditions such as 
Stuve–Wiedemann syndrome may also be involved. At birth, radiographs may distinguish OI 
type II, CD, and chondrodysplasias with bone mineralization defect, from HPP, but outwardly 
the distinction is difficult. In infancy and childhood, OI (typically type III in infancy or type 
IV later on) is the most common differential diagnosis, but also more rare disorders such as 
cleidocranial dysostosis, Cole–Carpenter syndrome, idiopathic juvenile osteoporosis, and 
renal osteodystrophy. In adult osteopenia/osteoporosis and more rarely osteoarthritis and 
pseudogout may be due to HPP. 
We perform genetic diagnosis of HPP and maintain the TNSALP gene mutation database [6] 
where over 300 mutations are reported. In our experience sequencing the 12 exons and 
intron/exons borders in the ALPL gene by Sanger methodology allows to detect more than 
95% of the HPP mutations [14] and [15]. Undetected mutations probably affect intronic or 
regulatory sequences, or correspond to large deletions partly detected by qPCR or semi-
quantitative methodologies like Quantitative Multiplex PCR of Short Fluorescent fragments 
QMPSF [16]. However the Sanger methodology is expensive and time-consuming, which 
prevents a strategy of one-time diagnosis including genes of differential diagnosis such as 
COL1A1 and COL1A2 responsible for most cases of OI [17], each harboring over 50 exons. 
This means that in case of negative result for ALPL, other genes had to be analyzed, 
lengthening the time before diagnosis. The emergence of Next Generation Sequencing (NGS) 
technologies allows one-time sequencing of several genes (targeted NGS) or even all the 
coding sequences of genes (exome sequencing) or the full genome, and diagnosis applications 
have been shown in endocrine disorders as well as in all domains of medical genetics [18], 
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[19] and [20]. We report here our 18-month experience in testing 46 patients for HPP and 
differential diagnosis by targeted NGS and show that this strategy is efficient and useful. 
2. Materials and methods 
2.1. Patients 
During the period Dec. 2013–Jul.2015 we tested for diagnosis purpose 46 patients by NGS 
including 13 fetuses. The patients were referred to us by obstetricians, rheumatologists, 
endocrinologists, dentists or geneticists. Forty-two were referred to us for suspicion of HPP 
on the basis of some clinical and/or biological symptoms. Two patients were referred for CD 
and 2 for skeletal dysplasia without clear suggestion of diagnosis. An informed consent was 
obtained in each case. 
2.2. Genes tested 
The array included genes for HPP diagnosis and differential diagnosis: ALPL, COL1A1, 
COL1A2 and SOX9. In addition we included genes dedicated to the identification of modifier 
genes of HPP (ANKH, ENPP1, FGFR3, PHOSPHO1, PTH1R, PTH2R, SPP1 and 
TNFRSF11A), and the study of variants in the regulatory region of ALPL (5000 bp upstream 
exon 1). We present here the results of patients tested for HPP diagnosis and differential 
diagnosis. Two multiplex PCR primer pools were obtained from Thermo Fisher Scientific 
(Ion Ampliseq™). They included primers for the amplification of the coding sequence and 
150 bp of exon/intron borders of these genes. The 380 amplicons covered more than 96% of 
the target coding sequences. Ninety-eight percent of the ALPL gene was covered 
corresponding to all the coding sequence and intron/exon borders except a small part of exon 
4. This led us to routinely perform sequencing of exon 4 by standard Sanger methodology. 
2.3. Sequencing procedure 
Sequencing was performed from 10 ng of genomic DNA by using the Ion Torrent Personal 
Genome Machine (PGM) according to the recommendations of the manufacturer 
(Thermofisher Scientific). All the mutations identified by NGS and reported here were 
confirmed by sequencing with Sanger methodology. 
2.4. Analysis 
2.4.1. Damaging effect of mutations 
The sequence variations were compared to human genome hg19. Identification of variants 
was performed with Variant Caller and Ion Reporter softwares (Thermo Fisher Scientific) and 
in silico prediction of their pathogenicity was performed by using the free access web servers 
POLYPHEN2 (http://genetics.bwh.harvard.edu/pph2/) [21], SIFT (http://sift.jcvi.org/) [22] 
and MUTATION TASTER (http://www.mutationtaster.org/) [23]. The effect of mutations on 
splicing was tested by using Human Splicing Finder web server (http://www.umd.be/HSF3/) 
[24]. 
2.4.2. Dominant effect of mutations 
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The prediction of dominant negative effect of mutations was performed by using 3D modeling 
of TNSALP [25] and [26]. Mutations affecting residues located in particular regions, 
especially the active site, the crown domain and the homodimer interface, were predicted to 
have a possible dominant effect [15] and [26]. 
2.4.3. Mutagenesis and expression of PHOSPHO1 (patient P12) 
Briefly the PHOSPHO1 c.95_97CCT deletion was introduced into a pCMV expression vector 
containing the human PHOSPHO1 coding sequence. The resulting construct was transiently 
transfected into COS-1 cells. The total activity of WT and c.95_97CCT mutant extracts was 
measured at 405 nm, using p-nitrophenyl phosphate (pNPP, 20 mM) as a substrate, at pH 9.8, 
and using 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (P-Etn) because PHOSPHO1 
shows high phosphohydrolase activity towards P-Etn. 
3. Results 
We present here the sequence variations detected in the genes tested for HPP or differential 
diagnosis, filtered with MAF (Minimum Allele Frequency) < 0.02. This allows the exclusion 
of common polymorphisms. 
Among the 46 tested patients 29 (63%) were negative for any mutation in the tested genes. 
Eleven of them were adults (43–91 yo) with stress or atypical fractures, low BMD and 
musculoskeletal pain and referred by rheumatologists for HPP. Among the patients tested for 
serum ALP, 5 presented with values below the normal range. Thirteen cases were fetuses with 
clinical manifestations compatible with HPP and referred by geneticists or obstetricians. The 
other cases were referred for odontoHPP (3 cases) and for suspicion of infantile HPP (1 case) 
or childhood HPP (1 case). 
In 17 cases (37%) a mutation was detected in ALPL, COL1A1, COL1A2 or SOX9. Except 
patient P12 all these patients were negative for the other genes included in the array. The 
results are summarized in Table 1 and Table 2. Only 67% (10/15) of patients referred for HPP 
were found to carry mutations in the ALPL gene and were therefore confirmed to have HPP ( 
Table 1). The others (5 cases) were found to harbor mutations in COL1A1 or COL1A2 
confirming the interest of testing these genes in routine diagnosis of HPP. 
Table 1.  
Distribution of positive genes versus referral. 
Genes with detected mutations
Referral Number of cases
ALPL COL1A1/COL1A2 SOX9
HPP 13 9 4 0 
HPP or OI 2 1 1 0 
CD 2 1 0 1 
Total 17 11 5 1 
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Table 2.  
Mutations detected in 17 patients tested with targeted NGS and estimation of their pathogenicity. 
Sequencing results correspond to sequence variations detected in ALPL or HPP differential diagnosis genes (see Material and methods), 
filtered with MAF (minor allele frequency) < 0.02. In silico prediction shows the predictions of the three free access web servers 
POLYPHEN2 (PP2), SIFT and MUTATION TASTER (MT). For PP2 and MT the scores range from 0 (benign) to 1 (damaging), while 
for SIFT they range from 1 (benign) to 0 (damaging). The threshold benign/damaging is 0.05 for SIFT and 0.90 for PP2. The score 
indicated by MT is a confidence score for the prediction that the mutation is disease-causing. 
“Previously reported mutation” indicates that the damaging effect of the mutation is established because it was previously described in 
affected patients. 
Case Referral Sequencing results In silico prediction MAF 
Suggested 
diagnosis 
P1 32 weeks fetus with short and curved long bones. Suspicion of HPP or OI 
ALPL 
c.550C > T (p.Arg184Trp) 
heterozygote 
Previously 
reported mutation 0 
Prenatal benign 
HPP 
ALPL 
c.984_986delCTT (p.Phe328del) 
heterozygote 
Previously 
reported mutation 0 
P2 Interrupted fetus with angulation of long bones, low mineralization. Suspicion of HPP ALPL 
c.1460C > T (p.Ala487Val) 
heterozygote 
PP2: 1 
SIFT: 0.01 
MT: 0.999 
3D: dimer 
interface 
0 
Perinatal HPP 
ALPL 
c.299C > T (p.Thr100Met) 
Previously 
reported mutation 0 P3 
Interrupted fetus (20 weeks) with 
osteochondrosysplasia: short long bones, 
deformation of long bones, mineralization 
deficiency: suspicion of HPP 
ALPL 
c.1258G > A (p.Gly420Ser) 
Previously 
reported mutation 0 
Perinatal HPP 
P4 18 mo female with loss of teeth and low ALP, her ALPL Previously 0 OdontoHPP 
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Case Referral Sequencing results In silico prediction MAF 
Suggested 
diagnosis 
twin is affected: suspicion of odontoHPP c.346G > A (p.Ala116Thr) 
heterozygote 
reported mutation
P5 59 yo female with spontaneous fractures and low ALP: 30 UI/L (35–120) Suspicion of HPP 
ALPL 
c.599G > A (p.Gly200Asp) 
heterozygote 
PP2: 0.994 
SIFT: 0.07 
MT: 0.999 
3D: nonspecific 
domain 
0 Adult HPP 
P6 46 yo man with femoral rift and low ALP: 26 U/L (41–120). Suspicion of HPP 
ALPL 
c.302_310delACAACACCA 
(p.Asn102_Asn104del) 
heterozygote 
Previously 
reported mutation 0 Adult HPP 
P7 28 yo female with low ALP and low mineralization (faire confirmer l'indication): suspicion of HPP 
ALPL 
c.1328C > T (p.Ala443Val) 
heterozygote 
Previously 
reported mutation 0 Adult HPP 
P8 
73 yo female with fractures and low AP: 17 UI/L 
(35–105) 
Suspicion of HPP 
ALPL 
c.203C > T (p.Thr68Met) 
heterozygote 
Previously 
reported mutation 0 Adult HPP 
P9 41 yo female with pain, tendon calcifications and low AP: 32 U/L (35–105). Suspicion of HPP 
ALPL 
c.1381G > A (p.Val461Ile) 
heterozygote 
PP2: 0.014 
SIFT: 0.68 
MT: 0.989 
3D: dimer 
interface 
0.006 ? 
P10 2 yo female with loss of teeth and low AP: 51 U/L (130–300). Suspicion of odontoHPP 
ALPL 
c.1292 T > C (p.Val431Ala) 
heterozygote 
PP2: 0.951 
SIFT: 0.04 
MT: 0.999 
3D: crown 
domain 
0 OdontoHPP 
P11 Interrupted fetus with sexual reversion and short ALPL PP2: 0.984 5 · 10− 4 CD 
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Case Referral Sequencing results In silico prediction MAF 
Suggested 
diagnosis 
stature: suspicion of CD c.436G > A (p.Glu146Lys) 
heterozygote 
SIFT: 0.02 
MT: 0.999 
3D: nonspecific 
domain 
COL1A2 c.1072G > A 
(p.Gly358Ser) heterozygote 
PP2: 1 
SIFT: 0 
MT: 0.999 
Previously 
reported mutation
0 
P12
Newborn with severe osteochondrodysplasia 
detected at 22 weeks, hypercalcemia, 
nephrocalcinosis, many fractures and repeatedly 
low AP: 95 U/L and 80 U/L (139–449). Suspicion 
of HPP PHOSPHO1 
c.95_97delCCT 
(p.Ser32del) heterozygote 
Na 0.012 
OI type III 
P13
Interrupted fetus (22 w) with fractures of long 
bones and metaphyseal features: suspicion of HPP 
or OI 
COL1A1 
c.1678G > A (p.Gly560Ser) 
heterozygote 
PP2: 1 
SIFT: 0 
MT: 0.999 
0 OI 
P14 88 yo female with atypical femoral fractures: suspicion of HPP 
COL1A2 
c.2123G > A (p.Arg708Gln) 
heterozygote 
PP2: 1 
SIFT: 0.01 
MT: 0.999 
0.0008 
Heritable 
disorder of 
connective 
tissue? 
P15
49 yo female with join pain, chondrocalcinosis and 
low AP: 25 UI/L (40–100) 
Suspicion of HPP 
COL1A1 
c.517G > A (p.Gly173Arg) 
heterozygote 
PP2: 0.958 
SIFT: 0.02 
MT: 0.999 
0 OI 
P16
16 yo female with low BMD (Zscore = − 2SD), 
diffuse demineralization and low AP: 91 UI/L 
(120–390) 
Suspicion of HPP 
COL1A2 
c.3712-32A > C heterozygote 
MT: 
polymorphism 
HSF: Probably 
damaging 
(splicing) 
0 ? 
P17 Fetus with short and incurved long bones: SOX9 na 0 CD 
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Case Referral Sequencing results In silico prediction MAF 
Suggested 
diagnosis 
suspicion of CD c.813_814insGACTCCGT 
(p.Val273fs) heterozygote 
 
3.1. ALPL mutations 
The fetus P1 was suspected to have OI or HPP on the basis of short and incurved long bones (< 3th percentile, femur: − 2.2 Zscore; humerus 
− 2.4 Zscore) observed at 32 weeks without fractures and with apparently normal mineralization. The heterozygous mutation c.550C > T 
(p.Arg184Trp) was detected. No other mutation was found. Screening for large deletions by qPCR was negative. The mutation p.Arg184Trp was 
previously reported in severe HPP when combined with another mutation [27], but also in moderate HPP (odonto and adult) at heterozygous state 
[15] and [28]. The dominant effect of the mutation was previously demonstrated by site-directed mutagenesis and transient expression in 
eukaryotic cells [28]. In addition we previously observed this heterozygous mutation in a case of prenatal benign HPP (our unpublished data). 
We therefore suggested that the fetus was affected with prenatal benign HPP. In this rare and particular form, the disease may be recessively or 
dominantly inherited [5], and when it is dominantly inherited the mutation is most often from maternal origin [3] and [5]. Here the mutation 
p.Arg184Trp was from maternal origin. Genetic counseling provided explanations about this form of HPP and was therefore reassuring. 
Examination of the baby at birth evidenced only a discreet bowing of the right femur. No other deformation was seen and X-ray showed normal 
mineralization. 
The fetus P2 was tested for ALPL gene mutations because of angulation of long bones and abnormal mineralization. The absence of wormian 
bones and callus did not suggested OI. We found the two heterozygous mutations c.984_986delCTT (p.Phe328del) from maternal origin and 
c.1460C > T (p.Ala487Val) from paternal origin. The mutation p.Ala487Val was not previously reported. In silico tools suggest a damaging 
effect of this mutation ( Table 2) and 3D modeling does not suggest a dominant negative effect. These results confirmed the diagnosis of severe 
HPP. 
The pregnancy of P3 was terminated at 20 weeks because of short and deformed long bones (below the 5th centile), associated with radial 
deviation of both hands. Post-natal X-rays revealed diffuse hypomineralization, short and bowed long-bones. The forearm bones were severely 
malformed. Autopsy confirmed the shortening of long bones and radial deviation of hands with presence of 5 rays. Bone histology showed a 
thickening of the hypertrophic cartilage, persisting cartilage islets in the diaphyseal bone and a defect of membranous ossification. Confirming 
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the diagnosis of severe HPP two heterozygous mutations were found in ALPL, c.299C > T 
(p.Thr100Met) from paternal origin and c.1258G > A (p.Gly420Ser) from maternal origin. 
We and others [26] and [29] previously reported these 2 mutations in severe HPP. 
Patients P4 and P10 were two young girls (18 mo and 2 yo, respectively) presenting with 
early loss of teeth. OdontoHPP was suspected. Serum ALP was found low (P4: 94 UI/L, 
normal range > 120; P10: 51 U/L normal range 130–300). The heterozygous mutations 
c.346G > A (p.Ala116Thr) in P4 and c.1292 T > C (p.Val431Ala) in P10 confirmed the 
diagnosis. The mutation p.A116T was previously reported to be responsible for dominant 
odontoHPP [28] and [30] while the mutation p.Val431Ala was not previously reported. In 
silico a damaging effect is predicted. In addition 3D modeling predicts a possible dominant 
negative effect due to the localization of Val431 in the crown domain. 
Five patients (P5-P9) presented with clinical features of adult HPP, mostly low 
mineralization, bone fractures without trauma, and when tested, low serum ALP (see Table 2). 
In each of these patients we found one ALPL heterozygous mutation which is coherent with 
the previous observations that moderate forms of HPP, especially adult and odontoHPP, are 
mostly due to heterozygous mutations [10] and [15]. The mutation p.Ala443Val was 
previously observed in a patient with adult HPP [15], the mutations p.Asn102_Asn104del, 
Thr68Met, and p.Val461Ile were previously observed in severe HPP, associated with others 
mutations, but the dominant negative effect of these mutations was not tested. However, 3D 
modeling suggests a possible dominant negative effect of p.Thr68Met and p.Val461Ile. The 
novel mutation found in P5, c.599G > A (p.Gly200Asp), was predicted to be damaging by in 
silico tools although the SIFT score (0.07) was slightly over the threshold (0.05). 3D 
modeling did not suggest a dominant negative effect of this mutation. 
P11 was a fetus with typical signs of CD, including bone bowing and sexual reversion (46,XY 
karyotype, female phenotype). For this fetus we did not find any mutation in SOX9 but the 
fetal DNA was degraded, probably due to fixation of cells in methanol/acetic acid, and a part 
of the gene (200 nucleotides in exon 3) could not be analyzed either by NGS or by Sanger 
methodology. Thus it was not possible to confirm CD. Interestingly we found in this patient 
the novel heterozygous ALPL mutation c.436G > A (p.Glu146Lys) from paternal origin. In 
silico this mutation is predicted damaging by the three prediction softwares, and 3D modeling 
suggests that this mutation does not have a dominant negative effect. So, for this patient 
clinically affected with CD, it is not clear whether the CD diagnosis may be confirmed neither 
there is a role of the ALPL mutation in the phenotype. 
3.2. COL1A1 and COL1A2 mutations 
P12 was a fetus diagnosed at 22 weeks with severe osteochondrodysplasia, very low 
mineralization and multiple fractures, suggesting HPP or OI. The pregnancy was pursued and 
among the features observed in the baby, nephrocalcinosis, repeatedly low serum ALP (80 
and 95 U/L, normal range 139–449), high Pyridoxal 5′-Phosphate (PLP) (213 nM, normal 
range < 60), hypercalcemia, hypercalciuria, absence of wormian bones and a large fontanelle 
were suggestive for HPP diagnosis. We did not find any mutation in ALPL but found the 
heterozygous COL1A2 mutation c.1072G > A (p.Gly358Ser) previously reported as 
responsible for OI. We also found the heterozygous sequence variation c.95_97delCCT 
(p.Ser32del) in PHOSPHO1. We hypothesized that this mutation, from paternal origin, could 
at least in part explain the atypical phenotype suggestive for HPP. However, in addition to its 
relatively high MAF (0.012), no differences in activity were detected by site-directed 
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mutagenesis for either pNPP or phosphoethanolamine substrates between wild type and 
mutant constructs (p = 0.29 and p = 0.23, respectively). This excludes a role of this variant in 
the phenotype although these in vitro tests do not perfectly reflect in vivo function conditions. 
P13 was a terminated fetus presenting with fractures of long bones and metaphyseal 
abnormalities, suggesting HPP or OI. The heterozygous mutation c.1678G > A (p.Gly560Ser) 
in COL1A1 was found, indicating that the fetus was affected with OI. This mutation was 
previously reported (ref [31] and R Dalgleish OI Variant Database 
(https://oi.gene.le.ac.uk/api/feed.php?select_db=COL1A1) in severe OI and predicted 
damaging by in silico tools ( Table 2). The substitution affects a glycine amino acid of the 
repeated motif (Gly-X-Y), which always results in severe damages because of space 
constraint in the collagen helix. 
Patient P14 was an 88 yo female presenting with atypical femoral fractures. Clinical and 
biological features of the patient will be extensively described by Funck-Brentano et al. 
(manuscript in preparation). We found the mutation c.2123G > A (p.Arg708Gln) in COL1A2. 
This mutation was previously reported in an atypical case of Marfan syndrome [32], another 
heritable disorders of connective tissue with OI and Ehlers–Danlos syndrome (EDS). The 
mutation affects a highly conserved arginine of a Gly-X-Y motif and in silico tools predict a 
damaging effect of the mutation. However no particular clinical sign of EDS or Marfan 
syndrome was found in the patient. 
Patient P15 was a 49 yo female patient suspected to have HPP because of low serum ALP 
(25 U/L, normal range 40–100), musculoskeletal pain and tendon calcifications. No ALPL 
mutation were detected but a heterozygous mutation c.517G > A (p.Gly173Arg) in COL1A1 
was found. This unreported mutation, that substitutes a glycine residue, is predicted 
damaging. 
Patient P16 was a 16 yo female presenting with low ALP and diffuse demineralization. A 
context of mental anorexia could explain these features. The patient is heterozygote for the 
COL1A2 mutation c.3712-32A > C predicted to affect splicing by Human Splicing Finder 
web server (http://www.umd.be/HSF3/). However it was described as a polymorphism by 
Mutation Taster with a probability of 0.999. The variant was observed once in Exome 
Aggregation Consortium (ExAC, http://exac.broadinstitute.org/) data resulting in an allele 
frequency of 8.3 · 10− 6. 
3.3. SOX9 mutations 
The fetus P17 was referred for CD testing because of short and incurved long bones. He 
carried the novel frameshift mutation c.813_814insGACTCCGT in SOX9, allowing us to 
confirm CD diagnosis. 
4. Discussion 
On the basis of clinical examination, imaging (X-Ray, ultrasound) and biological data (ALP, 
PLP, PEA), the distinction between HPP and its main differential diagnoses, CD and OI, is 
usually assumed to be possible without the need of genetic analysis, the latter simply 
confirming the diagnosis. However, patient records are often not exhaustive so that the 
distinction is not always possible, especially in prenatal context where unavailable tools (X-
ray, biology) make difficult the correct diagnosis. This is illustrated by our series where 2 
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fetuses suspected to have HPP and finally found to carry a COL1A1/A2 mutation, and another 
fetus carrying an ALPL mutation and suspected to have OI or HPP while no definitive 
argument could be made in favor of one of these diagnoses. Interestingly three of our adult 
patients were suspected to have HPP and were also found to carry COL1A1/A2 mutations, 
indicating that HPP and OI may be easily mixed up in prenatal context and in adults as well. 
Moreover, we noted that three of the patients with COL1A1/2 mutations were reported with 
low serum ALP, yet a marker of hypophosphatasia, and that in two of them none of the 
conditions that could explain these low levels (hypothyroidism, nutrition problem, 
bisphosphonates treatment…) were identified. Unfortunately, except patient P12, PLP and 
PEA levels were not measured in these patients. Given these results it was therefore of 
interest to design a test including ALPL, SOX9, COL1A1 and COL1A2 genes in order to 
improve diagnosis rate, turn-around time and costs. Up to date a total of 17 genetic causes of 
OI have been described [33] but mutations in COL1A1 and COL1A2 represent approximately 
90% of the cases in European populations [17]. The inclusion in the array of other OI genes as 
well as other conditions like cleidocranial dysostosis or Stuve–Wiedemann syndrome could 
still increase the detection rate of mutations. 
Excepted for ALPL mutations previously reported in HPP patients, assumed to be damaging, 
the pathogenicity of the mutations detected in this study was estimated by using the prediction 
softwares POLYPHEN2, SIFT and MUTATION TASTER. According to these tools, most of 
the mutations described here were predicted damaging, the three softwares giving the same 
prediction. Together with MAF results, these tools seem efficient to discriminate pathogenic 
mutations vs polymorphisms. However 2 mutations were not clearly predicted damaging or 
benign, c.1381G > A (p.Val461Ile) in ALPL and c.3712-32A > C in COL1A2. The mutation 
c.1381G > A (p.Val461Ile) found in patient P9 was previously reported by Nielson et al. [12] 
in a patient with low BMD and low ALP. The three softwares do not suggest a damaging 
effect while 3D modeling indicates that Val461 is close to the homodimer interface. The 
variant was not found in 148 controls [12] but the minor allele frequency (MAF) was 0.6% 
(ExAC data), which may correspond to a rare polymorphism or a mutation. Alignment of 58 
mammal TNSALPs shows that position 461 tolerate conservative changes [34], which is the 
case of Val → Ile change. So although this variant was observed twice in patients with low 
BMD and low AP ( [12] and this study) it remains possible that it is a benign polymorphism. 
This is also the case of the COL1A2 intronic mutation c.3712-32A > C found in patient P16. 
According to Human Splicing Finder the mutation could be damaging but MUTATION 
TASTER predicted a polymorphism, due to its intronic position and ExAC data. Because of 
specific HPP features, especially repeatedly low serum ALP, and to the uncertain significance 
of the COL1A2 mutation, it remains possible that the patient carried an undetected mutation of 
the ALPL gene. 
In conclusion our results confirm the overlap of OI and HPP features in prenatal context, but 
also in adults, so that a testing strategy including at least COL1A1, COL1A2 and ALPL genes 
is proven useful and efficient. 
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